(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 December 2022 (22.12.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/266510 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61K 33/00* (2006.01)
A61K 31/00 (2006.01) *A61K 38/00* (2006.01)
A61K 31/70 (2006.01) *C07K 16/22* (2006.01)

(21) International Application Number:
PCT/US2022/034103

(22) International Filing Date:
17 June 2022 (17.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/212,473 18 June 2021 (18.06.2021) US

(71) Applicant: **GENZYME CORPORATION** [US/US]; 450 Water Street, Cambridge, Massachusetts 02141 (US).

(72) Inventors: **BANGARI, Kiran Rana**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **LATYPOV, Ramil**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **MCCOY, Timothy**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **PATKE, Sanket**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US).

(74) Agent: **LI, Z., Ying** et al.; Steptoe & Johnson LLP, 1330 Connecticut Avenue, N.W., Washington, District of Columbia 20036 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ANTI-TGF-BETA ANTIBODY FORMULATIONS AND THEIR USE

(57) Abstract: The present disclosure provides pharmaceutical compositions comprising anti-TGF-β antibodies and methods of use thereof.

WO 2022/266510 A1